Calibre raises £2.4m pre-seed to identify root health drivers via causal AI
This article covers Calibre, a healthtech startup, which has raised £2.4m in a pre-seed funding round to build a membership-style service combining clinical care, diagnostic testing and causal AI to identify the root drivers of a person’s health and deliver a personalised, evolving plan. The development aims to support UK adults seeking preventive, clinically informed health advice and to progress Calibre towards operating its own regulated clinical service.
Calibre, a healthtech startup, has raised £2.4 million in a pre-seed funding round to build a membership-style service that combines clinical care, diagnostic testing and causal AI to identify the root drivers of a person’s health and deliver an evolving, personalised plan. The raise will fund product development and clinical integration as Calibre moves from pilot work with a partner provider towards its own regulated offering.
Why it matters
UK adults spend a growing proportion of life in poor health, and policymakers and consumers are increasingly focused on prevention rather than episodic treatment. Calibre’s pitch addresses a simple gap: many people do not know what their body needs and turn to generic advice or conversational AI tools that lack clinical context. The company cites several indicators of that gap — 74% of UK adults say good health habits are key to preventing illness, 37% find it hard to know what their body needs, and roughly 230 million health-related queries are sent to ChatGPT each week — as reasons why a clinician-led, data-driven approach could matter.
Inside the product
Calibre combines a person’s medical history, daily behaviour and environmental context with diagnostic testing to surface “underlying health drivers,” according to the company. The platform pairs clinician input with causal AI models to produce a continuously updated health assessment and a personalised plan aimed at improving daily energy and reducing long-term risks. Clinical care is currently delivered through partner DocTap, a Care Quality Commission (CQC) registered provider, while Calibre has submitted its own CQC application as it moves towards operating its own regulated clinical service.
Who are the investors?
The round was led by Amino Collective, with participation from Daybreak Ventures, Cocoa Ventures, Timo Boldt and Maximilian Tayenthal.
In the announcement, Manuel Grossmann, Partner at Amino Collective, said:
Consumer health has been full of tools that track everything and change nothing. Calibre is changing health outcomes by understanding what's actually driving them, and helping you to take action.
In the announcement, Timo Boldt, Founder & CEO at Gousto, said:
I built Gousto on the belief that food is medicine. But food is only a part of the picture, and the UK's health crisis makes that clear as people are spending decades of their lives in poor health. What's missing is the full picture and the personalised insight to act on it. That’s where Calibre comes in.
If you're researching potential backers in this space:
- Explore our list of healthtech venture capital firms in the UK
- Browse our directory of healthtech angel investors in the UK
Founder perspective
Calibre was co-founded by Alexander Weber, Ben Levy and Dr Reinhold Innerhofer. Weber previously served as Chief Growth Officer at N26, Levy has built and scaled healthtech companies including Elvie (a femtech device company) and Manual, and Dr Innerhofer is a medical doctor and sports scientist who has worked with Olympic medallists and world champions. Together the team positions clinical credibility alongside product and growth experience.
In the announcement, Alexander Weber, Co-founder & CEO at Calibre, said:
Over the last years, we have been witnessing a generational shift in how people think about health - from health being the absence of sickness to it being the foundation to live life fully. Left alone by the system, people are now in the era of health guesswork. Calibre is what comes next: a proactive health partner for life that deeply understands your full picture, tells you what's actually driving your health, and guides you as your health evolves. Our vision is a world where everyone has the health to realise their potential.
The bigger picture
Calibre’s product sits at the intersection of consumer health, diagnostics and applied AI — an area that has attracted growing attention but also regulatory scrutiny. For consumer-facing health products in the UK, partnering with CQC-registered providers or securing registration of their own services is a practical step toward credibility and scale. The company’s approach — tying diagnostics to clinician oversight and causal modelling — reflects a broader move away from standalone trackers toward integrated, clinically informed services.
This raise is one of several recent early-stage funding moves in UK healthtech aimed at preventative care and personalised medicine. As consumer expectations and AI tools evolve, startups that can combine clinical governance, reliable diagnostics and actionable insight will be better placed to win trust and regulatory clearance across the UK and Europe.
They've invested in Calibre
Get to know these healthtech investors
Click here for a full list of 7,589+ startup investors in the UK